Navigation Links
Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Date:5/12/2010

Acquisition Extends Consulting and Implementation Capabilities and Software Offerings of Xybion Corporation

(PRWEB) May 12, 2010 -- Xybion Corporation announced today that it has completed the acquisition of substantially all of the operating assets of Stelex and Vital-Path from GE Healthcare. The terms of the transactions were not disclosed.

Stelex and Vital-Path, based in Bensalem, PA is a strategic addition to Xybion’s enterprise software and consulting solutions focus for the life sciences, finance, manufacturing and other regulated industries. Stelex and Vital-Path provide a range of products and services to regulated industries such as:

- Asset and Facilities Management solutions including services and support for IBM’s Maximo, a leading software solution that enables the user to develop comprehensive programs for preventive, predictive, routine and unplanned maintenance for assets and facilities

- Enterprise Content Management and Migration solutions to assist clients in taking control of their mission critical content and to seamlessly share data among disparate departmental content repositories

- Regulatory Compliance solutions and System integration and implementation services for regulated industries.

The acquisition will extend Xybion’s software, consulting and Implementation capabilities and increase the company’s enterprise client base.

“The addition of Stelex and Vital-Path will advance Xybion’s vision of being the enterprise system partner of choice for life sciences product companies and CROs worldwide,” said Dr. Pradip K. Banerjee, Chairman and CEO of Xybion Corporation. “Stelex’s solutions, talent and customers enhance Xybion’s business and extend our ability to deliver compelling products and services to enterprise customers. Stelex’s reputation in quality assurance and validation consulting for the pharmaceutical and life science industry is unparalleled. In addition, their experience and positioning with partners like IBM and OpenText complement Xybion’s expansion into other markets with a focus on business process and quality management improvements in both regulated and non-regulated industries."

“This is an exciting milestone for our company, and we look forward to scaling our growth as part of Xybion,” said Tony Kashani, president of Stelex. “Xybion’s global reach, widely recognized brand and customer relationships make an ideal fit for Stelex. Like Xybion, we have our roots in the life sciences and have expanded our opportunities with offerings in other markets. Our combined teams will create exciting growth opportunities for both of our customers and our employees. We look forward to working with the Xybion team to ensure a rapid and seamless transition.”

Stelex’s Bensalem, PA office will function as Xybion’s Center of Excellence for the Xybion consulting and Implementation business. The acquisition more than doubles Xybion’s size and adds significant staff capabilities in development, sales and marketing for Xybion. Xybion currently has offices in the United States, Canada, and Europe.

About Xybion
Xybion is the enterprise system partner of choice for life sciences product companies and research organizations worldwide for end-to-end needs in the pre-clinical R&D, Quality, and Regulatory risk and compliance management solutions. In addition to Pristima™, Pristima™ VM, Providence, eQRP, and eQCM, Xybion also provides professional services, consulting, training and validation activities to clients around the world. Learn more about Xybion at xybion.com.

About Stelex
For over twenty years, Stelex has provided solutions and services to improve business processes for regulated and non-regulated industries, by providing the expertise, strategies and technology to help clients mitigate risk, enhance productivity and increase profitability. Stelex is a client-centered organization, tailoring solutions to address the specific requests and needs of clients. Stelex assists clients in meeting requirements and achieving their business goals. Learn more about Stelex at stelex.com.

###

Read the full story at http://www.prweb.com/releases/Xybion/Stelex/prweb3983884.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management
2. Korea Institute of Toxicology Implementing Xybion's Pristima™
3. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
4. Hendrick Construction Completes Oak Ridge National Laboratory Expansion
5. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
6. Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.
7. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
8. EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
9. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
10. Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
11. Neuralstem Completes $5.25 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
Breaking Biology News(10 mins):